Complete Filing Data
Contineum Therapeutics, Inc. reported Stockholders Equity of $260.99 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Contineum Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $189.0K | -$37.0K | $184.0K |
| Net Income Loss | -$60.0M | -$42.3M | $22.7M |
| Research And Development Expense | $51.5M | $38.4M | $27.6M |
| Other Nonoperating Income Expense | -$165.0K | -$163.0K | -$177.0K |
| Operating Income Loss | -$68.1M | -$50.9M | $16.1M |
| Operating Expenses | $68.1M | $50.9M | $33.9M |
| Nonoperating Income Expense | $8.1M | $8.6M | $7.1M |
| General And Administrative Expense | $16.5M | $12.5M | $6.3M |
| Comprehensive Income Net Of Tax | -$59.8M | -$42.3M | $22.9M |
| Marketable Securities Gain Loss Excluding Other Than Temporary Impairments | $12.0K | $5.0K | -$19.0K |
| Interest Expense Nonoperating | $0.00 | $208.0K | |
| Income Tax Expense Benefit | $0.00 | $450.0K | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$42.3M | $23.2M | |
| Revenue From Contract With Customer Excluding Assessed Tax | $0.00 | $50.0M | |
| Net Income Loss Available To Common Stockholders Diluted | -$42.3M | $274.0K | |
| Net Income Loss Available To Common Stockholders Basic | -$42.3M | $3.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | $118.0K | -$23.0K | $99.0K | $688.0K | -$69.0K | -$166.0K | -$24.0K | -$56.0K | $67.0K |
| Net Income Loss | -$12.8M | -$16.0M | -$16.0M | -$10.3M | -$9.0M | -$8.4M | -$6.3M | $41.6M | -$4.8M |
| Research And Development Expense | $11.0M | $14.1M | $13.7M | $9.7M | $7.9M | $7.8M | $6.5M | $9.5M | $3.6M |
| Other Nonoperating Income Expense | $183.0K | -$167.0K | -$130.0K | -$34.0K | -$77.0K | -$6.0K | -$36.0K | -$76.0K | -$18.0K |
| Operating Income Loss | -$14.9M | -$17.9M | -$18.1M | -$13.0M | -$10.9M | -$9.9M | -$8.1M | $38.9M | -$5.1M |
| Operating Expenses | $14.9M | $17.9M | $18.1M | $13.0M | $10.9M | $9.9M | $8.1M | $11.1M | $5.1M |
| Nonoperating Income Expense | $2.4M | $1.9M | $2.1M | $2.7M | $1.9M | $1.5M | $1.7M | $3.4M | $291.0K |
| General And Administrative Expense | $3.9M | $3.8M | $4.4M | $3.2M | $3.0M | $2.2M | $1.6M | $1.6M | $1.5M |
| Comprehensive Income Net Of Tax | -$12.7M | -$16.1M | -$15.9M | -$9.6M | -$9.1M | -$8.6M | -$6.3M | $41.5M | -$4.8M |
| Marketable Securities Gain Loss Excluding Other Than Temporary Impairments | $2.0K | $0.00 | -$24.0K | ||||||
| Interest Expense Nonoperating | $0.00 | $0.00 | $0.00 | $0.00 | $116.0K | $92.0K | |||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | -$118.0K | $729.0K | $0.00 | |||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$10.3M | -$9.0M | -$8.4M | -$6.4M | $42.3M | -$4.8M | |||
| Revenue From Contract With Customer Excluding Assessed Tax | $0.00 | $0.00 | $0.00 | $50.0M | |||||
| Net Income Loss Available To Common Stockholders Diluted | -$10.3M | -$9.0M | -$6.3M | $2.9M | |||||
| Net Income Loss Available To Common Stockholders Basic | -$10.3M | -$9.0M | -$6.3M | $5.9M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $261.0M | $198.1M | -$67.9M | -$93.2M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $75.6M | $21.9M | $15.5M | $5.6M |
| Operating Lease Right Of Use Asset | $7.6M | $5.5M | $719.0K | |
| Retained Earnings Accumulated Deficit | -$177.4M | -$117.4M | -$75.1M | |
| Property Plant And Equipment Net | $830.0K | $989.0K | $678.0K | |
| Prepaid Expense And Other Assets Current | $5.0M | $1.6M | $2.5M | |
| Other Assets Noncurrent | $256.0K | $3.0K | $1.3M | |
| Operating Lease Right Of Use Asset Amortization Expense | $1.1M | $872.0K | $965.0K | |
| Operating Lease Liability Noncurrent | $5.9M | $4.8M | $108.0K | |
| Operating Lease Liability Current | $2.3M | $1.5M | $464.0K | |
| Marketable Securities Current | $187.3M | $182.8M | $109.7M | |
| Liabilities Current | $9.7M | $10.0M | $5.5M | |
| Liabilities And Stockholders Equity | $276.6M | $212.8M | $130.4M | |
| Liabilities | $15.7M | $14.8M | $5.7M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $53.7M | $6.4M | $10.0M | |
| Cash And Cash Equivalents At Carrying Value | $75.6M | $21.9M | $15.5M | |
| Assets Current | $267.9M | $206.4M | $127.7M | |
| Assets | $276.6M | $212.8M | $130.4M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $260.0K | $71.0K | $108.0K | |
| Accrued Liabilities Current | $6.4M | $6.7M | $4.4M | |
| Accounts Payable Current | $1.0M | $1.8M | $635.0K | |
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | |
| Reclassifications Of Warrants From Liability To Equity | $0.00 | $216.0K | $0.00 | |
| Unrealized Gain Loss Of Investor Rights And Obligations Liability | $0.00 | $2.9M | ||
| Reclassification Of Deferred Offering Costs To Equity | $343.0K | $0.00 | ||
| Temporary Equity Carrying Amount Attributable To Parent | $0.00 | $192.6M | ||
| Repayments Of Long Term Debt | $0.00 | $3.8M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $180.5M | $171.4M | $184.8M | $210.2M | $217.5M | -$75.6M | -$61.1M | -$55.4M | -$97.5M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $42.6M | $20.8M | $22.5M | $40.9M | $77.2M | $16.3M | $17.5M | $52.1M | $9.1M |
| Operating Lease Right Of Use Asset | $4.8M | $5.0M | $5.2M | $231.0K | $474.0K | ||||
| Retained Earnings Accumulated Deficit | -$162.2M | -$149.4M | -$133.4M | -$102.8M | -$92.6M | -$83.6M | |||
| Property Plant And Equipment Net | $880.0K | $856.0K | $891.0K | $888.0K | $801.0K | $756.0K | |||
| Prepaid Expense And Other Assets Current | $2.5M | $1.4M | $1.4M | $1.2M | $1.7M | $1.8M | |||
| Other Assets Noncurrent | $266.0K | $186.0K | $4.0K | $3.0K | $3.0K | $2.6M | |||
| Operating Lease Right Of Use Asset Amortization Expense | $233.0K | $244.0K | $238.0K | ||||||
| Operating Lease Liability Noncurrent | $4.0M | $4.3M | $4.5M | $0.00 | $113.0K | $111.0K | |||
| Operating Lease Liability Current | $1.5M | $1.5M | $1.5M | $611.0K | $484.0K | $474.0K | |||
| Marketable Securities Current | $139.8M | $154.7M | $168.2M | $173.0M | $141.4M | $101.6M | |||
| Liabilities Current | $6.4M | $7.2M | $8.9M | $5.8M | $3.7M | $6.2M | |||
| Liabilities And Stockholders Equity | $190.8M | $182.9M | $198.3M | $216.0M | $221.4M | $123.6M | |||
| Liabilities | $10.4M | $11.5M | $13.5M | $5.8M | $3.9M | $6.6M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $527.0K | $738.0K | $3.5M | ||||||
| Cash And Cash Equivalents At Carrying Value | $42.6M | $20.8M | $22.5M | $40.9M | $77.2M | $16.3M | |||
| Assets Current | $184.9M | $176.8M | $192.1M | $215.1M | $220.3M | $119.7M | |||
| Assets | $190.8M | $182.9M | $198.3M | $216.0M | $221.4M | $123.6M | |||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $265.0K | $147.0K | $170.0K | $561.0K | -$127.0K | -$58.0K | |||
| Accrued Liabilities Current | $4.1M | $3.7M | $3.8M | $3.8M | $2.5M | $5.2M | |||
| Accounts Payable Current | $786.0K | $2.0M | $3.6M | $1.4M | $734.0K | $570.0K | |||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Reclassifications Of Warrants From Liability To Equity | |||||||||
| Unrealized Gain Loss Of Investor Rights And Obligations Liability | $0.00 | $0.00 | $0.00 | $2.9M | |||||
| Reclassification Of Deferred Offering Costs To Equity | |||||||||
| Temporary Equity Carrying Amount Attributable To Parent | $0.00 | $0.00 | $192.6M | ||||||
| Repayments Of Long Term Debt | $0.00 | $625.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Share Based Compensation | $10.0M | $6.8M | $2.2M |
| Proceeds From Stock Options Exercised | $219.0K | $405.0K | $159.0K |
| Proceeds From Sale And Maturity Of Marketable Securities | $159.0M | $157.2M | $76.7M |
| Payments To Acquire Property Plant And Equipment | $231.0K | $514.0K | $414.0K |
| Payments To Acquire Marketable Securities | $162.5M | $226.4M | $141.9M |
| Net Cash Provided By Used In Operating Activities | -$55.3M | -$32.8M | $19.3M |
| Net Cash Provided By Used In Investing Activities | -$3.7M | -$69.7M | -$65.6M |
| Net Cash Provided By Used In Financing Activities | $112.7M | $109.0M | $56.2M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $3.4M | -$887.0K | $1.3M |
| Increase Decrease In Operating Lease Liability | -$1.3M | $66.0K | -$1.3M |
| Increase Decrease In Accrued Liabilities | -$516.0K | $2.3M | $1.6M |
| Increase Decrease In Accounts Payable | -$869.0K | $1.1M | $0.00 |
| Depreciation Depletion And Amortization | $323.0K | $258.0K | $195.0K |
| Increase Decrease In Other Noncurrent Assets | -$3.0K | -$937.0K | -$7.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|
| Share Based Compensation | $2.6M | $768.0K | $494.0K |
| Proceeds From Stock Options Exercised | $24.0K | $122.0K | $8.0K |
| Proceeds From Sale And Maturity Of Marketable Securities | $48.7M | $39.5M | $18.6M |
| Payments To Acquire Property Plant And Equipment | $47.0K | $147.0K | $52.0K |
| Payments To Acquire Marketable Securities | $33.7M | $30.6M | $9.2M |
| Net Cash Provided By Used In Operating Activities | -$14.4M | -$8.0M | -$5.2M |
| Net Cash Provided By Used In Investing Activities | $14.9M | $8.7M | $9.4M |
| Net Cash Provided By Used In Financing Activities | $24.0K | -$18.0K | -$617.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$203.0K | -$713.0K | $60.0K |
| Increase Decrease In Operating Lease Liability | -$257.0K | $12.0K | -$263.0K |
| Increase Decrease In Accrued Liabilities | -$2.9M | -$380.0K | -$978.0K |
| Increase Decrease In Accounts Payable | $1.8M | -$70.0K | $282.0K |
| Depreciation Depletion And Amortization | $78.0K | $61.0K | $73.0K |
| Increase Decrease In Other Noncurrent Assets | $0.00 | -$5.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 27.7M | 19.4M | 2.3M |
| Earnings Per Share Basic | $-2.17 | $-2.18 | $1.36 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Temporary Equity Shares Outstanding | 0.00 | 15.9M | |
| Weighted Average Number Of Diluted Shares Outstanding | 27.7M | 19.4M | 3.4M |
| Earnings Per Share Diluted | $-2.17 | $-2.18 | $0.08 |
| Common Stock Shares Authorized | 220.0M | ||
| Temporary Equity Shares Issued | 0.00 | 15.9M | |
| Temporary Equity Shares Authorized | 0.00 | 16.9M | |
| Temporary Equity Par Or Stated Value Per Share | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 28.1M | 25.9M | 25.9M | 25.7M | 23.4M | 2.4M | 2.3M | 2.3M | 2.3M | |
| Earnings Per Share Basic | $-0.45 | $-0.62 | $-0.62 | $-0.40 | $-0.39 | $-3.55 | $-2.69 | $2.56 | $-2.12 | |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Temporary Equity Shares Outstanding | 0.00 | 0.00 | ||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 25.7M | 23.4M | 2.3M | 3.5M | ||||||
| Earnings Per Share Diluted | $-0.40 | $-0.39 | $-2.69 | $0.84 | ||||||
| Common Stock Shares Authorized | 39.6M | 39.6M | ||||||||
| Temporary Equity Shares Issued | 0.00 | 0.00 | 15.9M | |||||||
| Temporary Equity Shares Authorized | 0.00 | 0.00 | 16.9M | |||||||
| Temporary Equity Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $10.0M | $6.8M | $2.2M |
| Stock Issued During Period Value Stock Options Exercised | $219.0K | $405.0K | $159.0K |
| Investment Income Interest | $8.2M | $8.9M | $4.6M |
| Fair Value Adjustment Of Warrants | $0.00 | $106.0K | -$5.0K |
| Investment Income Net Amortization Of Discount And Premium | $791.0K | $3.9M | $2.7M |
| Additional Paid In Capital | $438.1M | $315.4M | $7.1M |
| Stock Issued During Period Value New Issues | $107.9M | $0.00 | |
| Payment Of Financing And Stock Issuance Costs | $256.0K | $0.00 | $343.0K |
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $6.2M | $10.9M | $110.0K |
| Stock Issued During Period Shares Stock Options Exercised | 42.7K | 157.1K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.6M | $2.4M | $2.6M | $2.3M | $1.5M | $768.0K | $477.0K | $489.0K | $494.0K |
| Stock Issued During Period Value Stock Options Exercised | $173.0K | $24.0K | $13.0K | $13.0K | $122.0K | $83.0K | $47.0K | $8.0K | |
| Investment Income Interest | $2.0M | $2.0M | $2.3M | $2.7M | $2.0M | $1.6M | $1.7M | $679.0K | $401.0K |
| Fair Value Adjustment Of Warrants | $0.00 | $0.00 | $0.00 | $0.00 | -$11.0K | $117.0K | $0.00 | -$2.0K | $0.00 |
| Investment Income Net Amortization Of Discount And Premium | $285.0K | $1.0M | $261.0K | ||||||
| Additional Paid In Capital | $342.4M | $320.6M | $318.0M | $312.5M | $310.2M | $8.0M | |||
| Stock Issued During Period Value New Issues | $19.0M | $107.9M | $0.00 | $0.00 | |||||
| Payment Of Financing And Stock Issuance Costs | $0.00 | $140.0K | |||||||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $10.9M | $7.0K | $103.0K | ||||||
| Stock Issued During Period Shares Stock Options Exercised | 17.0K | 34.9K |
Most recent annual filing with the SEC: March 5, 2026
Data sourced from SEC EDGAR public filings as of August 8, 2026.